EANS-Adhoc: SYGNIS Pharma AG / SYGNIS announces the adaptation of its organisation to the new business activity

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Strategic management decisions/Company Information
20.12.2012

Ad hoc-Release according to § 15 WpHG

SYGNIS announces the adaptation of its organisation to the new
business activity

Heidelberg 20 December 2012 - SYGNIS Pharma AG (Frankfurt: LIO1;
ISIN: DE000A1RFM03, Prime Standard) announced today the
discontinuation of its therapeutic R&D project KIBRA and the
adaptation of its organisation to the new business activity. At the
Heidelberg site the staff will be reduced by 10 employees. These
measures are implemented to concentrate the financial resources on
the development and marketing of novel technologies in molecular
biology in line with the new corporate strategy. This new business
was acquired in 2012 by joining forces with the Spanish X-Pol
Biotech. Relating to the reduction of staff, the Company expects a
one-time total expense of up to EUR 0.2 million. In addition non-cash
related impairments with regard to intangible assets of up to EUR 3.2
million could occur. **** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG
Peter Willinger
CFO

Tel: +49 6221 454 836
Email: willinger@sygnis.de

### Disclaimer This publication is intended for information only and
constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1RFM03
indexes:
stockmarkets:
language: English